Cytek Biosciences appoints William McCombe as CFO, reaffirms 2024 revenue guidance

Cytek Biosciences, Inc.

Patrik Jeanmonod steps down as CFO to become Head of Corporate Development Analytics, effective March 17, 2024.
William McCombe appointed CFO effective March 18, 2024; base salary $420,000, target bonus 50%, equity grant $1.25M.
McCombe previously CFO at Velo3D, HZO, and Maxar Technologies; over 20 years investment banking experience.
Cytek reaffirms 2024 revenue guidance of $203M-$213M (5-10% growth) and expectation of positive net income.
No disagreement cited for Jeanmonod's transition; company reiterates 2024 outlook unchanged.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Patrik Jeanmonod

Chief Financial Officer

CTKB · Cytek Biosciences, Inc.

Effective: 2024-03-17
Successor: William McCombe
Filed: March 19, 2024, 7:59 PM ET

Effective as of March 17, 2024, Patrik Jeanmonod stepped down from his position as the Chief Financial Officer of Cytek Biosciences, Inc. (the “Company”) to serve as the Company’s Head of Corporate Development Analytics.

Appointed

William McCombe

Chief Financial Officer

CTKB · Cytek Biosciences, Inc.

Effective: 2024-03-18
Filed: March 19, 2024, 7:59 PM ET

On March 19, 2024, the Board of Directors of the Company announced the appointment of William (“Bill”) McCombe as the Chief Financial Officer of the Company, effective March 18, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrik Jeanmonod changed role as Chief Financial Officer at Cytek Biosciences, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

Effective as of March 17, 2024, Patrik Jeanmonod stepped down from his position as the Chief Financial Officer of Cytek Biosciences, Inc. (the “Company”) to serve as the Company’s Head of Corporate Development Analytics.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William McCombe was appointed as Chief Financial Officer at Cytek Biosciences, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 19, 2024, the Board of Directors of the Company announced the appointment of William (“Bill”) McCombe as the Chief Financial Officer of the Company, effective March 18, 2024.

View on SEC.gov

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-071467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.